- Home
- RDHL
as of 09-01-2026 3:46pm EST
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
| Founded: | 2009 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 4.0M | IPO Year: | 2012 |
| Target Price: | N/A | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $0.57 - $2.79 | Next Earning Date: | 04-27-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 381.91% | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Stock Insider Trading Activity of Redhill Biopharma Ltd. (RDHL)
Chief Operating Officer
Avg Cost/Share
$0.00
Shares
14,130,000
Total Value
$1,413.00
Owned After
218,780,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Raday Gilead | RDHL | Chief Operating Officer | Jul 10, 2026 | Sell | $0.00 | 14,130,000 | $1,413.00 | 218,780,000 |
Compare RDHL vs Leading Stocks
See how RDHL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RDHL Redhill Biopharma Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.